Evidence map›Paper›PMID 36482498›Full record

ArticleClinical and experimental reproductive medicine2022

Therapeutic effect of Ferula assa-foetida oleo-gum resin in rats with letrozole-induced polycystic ovary syndrome.

Amir Shieh, Seyyed Majid Bagheri, Maryam Yadegari, Davoud Javidmehr, Zeinab Farhadi

Open access · diamondAbstract read
In one paragraph

Article in Clinical and experimental reproductive medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Treatment of D-galactose-induced rat polycystic ovarian condition usingJournal of advanced veterinary and animal research · 2024
    Article
  6. Nephroprotective Effect ofCurrent pharmaceutical design · 2024
    Article
  7. Review of potential spermatogenic and aphrodisiac effects of the Ferula genus.Clinical and experimental reproductive medicine · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Amir ShiehDepartment of Physiology, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Seyyed Majid BagheriDepartment of Physiology, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Maryam YadegariDepartment of Anatomy, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Davoud JavidmehrDepartment of Embryology, Research Institute of Reproductive Sciences, Royan Research Institute, Iran.
Zeinab FarhadiDepartment of Physiology, Faculty of Medicine, Kerman University of Medical Sciences, Kerman, Iran.
Shahid Sadoughi University of Medical Sciences and Health Services · IRKerman University of Medical Sciences · IRRoyan Institute · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveAsafoetida is a gum derived from Ferula assa-foetida, which is used in traditional Iranian medicine to treat some reproductive system disorders. The effects of asafoetida on ovarian tissue, expression of certain genes associated with polycystic ovary syndrome (PCOS), and levels of liver, kidney, and blood cell factors after treatment in a rat model were investigated.

methodsThirty rats were divided into five groups: normal, polycystic, and treatment with three doses of asafoetida (12.5, 25, and 50 mg/kg for 3 weeks after PCOS induction). PCOS was induced by letrozole at a dose of 1 mg/kg administered orally for 3 weeks. Blood samples were taken, and the ovaries were removed and prepared for histomorphometric examination. Liver and kidney parameters were measured. The mRNA expression levels of luteinizing hormone receptor, CYP11A1, adenosine monophosphate-activated protein kinase, adiponectin, and adiponectin receptors 1 and 2 were also measured by real-time polymerase chain reaction.

resultsThe levels of liver, kidney, and blood parameters did not significantly differ between the treatment groups and the control group. At doses of 25 and 50 mg/kg, ovarian histopathology, especially the thicknesses of the theca and granulosa layers, was significantly improved relative to the PCOS group. The expression of target genes also improved in the 25 and 50 mg/kg treatment groups.

conclusionAsafoetida can be used to treat PCOS as a complementary approach to conventional therapies. Asafoetida appears to act by regulating and activating metabolic and ovarian cycle enzymes.

Indexed as

AsafoetidaMetabolic syndromePolycystic ovary syndrome

Identifiers

PMID36482498
PMCPMC9732079
OpenAlexW4309828068

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.